Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
AAV vectors are widely used in gene therapy for their strong therapeutic potential
Access to genomic testing, not therapy cost, is the biggest challenge
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The perinatology CME at Navi Mumbai brought together more than 100 obstetricians, pediatricians, and neonatologists
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Subscribe To Our Newsletter & Stay Updated
